在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

CTAG1A Antibody

  • 中文名稱:
    CTAG1A兔多克隆抗體
  • 貨號:
    CSB-PA825329
  • 規格:
    ¥2024
  • 圖片:
    • Immunohistochemical analysis of paraffin-embedded Human gastric cancer tissue using at dilution 1/25.
    • Immunohistochemical analysis of paraffin-embedded Human thyroid cancer tissue using at dilution 1/25.
  • 其他:

產品詳情

  • 產品名稱:
    Rabbit anti-Homo sapiens (Human) CTAG1A Polyclonal antibody
  • Uniprot No.:
  • 基因名:
  • 宿主:
    Rabbit
  • 反應種屬:
    Human,Mouse,Rat
  • 免疫原:
    Synthetic peptide corresponding to a region derived from internal residues of Human Cancer/testis antigen 1
  • 免疫原種屬:
    Homo sapiens (Human)
  • 克隆類型:
    Polyclonal
  • 純化方式:
    Antigen Affinity Purified
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 產品提供形式:
    Liquid
  • 應用范圍:
    ELISA,IHC
  • 推薦稀釋比:
    Application Recommended Dilution
    IHC 1:50-1:100
  • Protocols:
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

  • 基因功能參考文獻:
    1. Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin. PMID: 29058035
    2. A significant association was found between AKAP4 gene expression and metastasis (P-value: 0.045), expression of the CTAG1B (NY-ESO-1) gene was not observed in our cases. PMID: 29480665
    3. In 22 melanoma patients with stage III lymph node metastasis, overall survival was significantly higher in the XAGE-1b and NY-ESO-1 double-negative group than in the other groups. PMID: 28105694
    4. The present results indicate the strong humoral immune response against NY-ESO-1 in natural human T-cell leukemia virus type 1 infection, irrespective of the clinical status. PMID: 28716148
    5. some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers. PMID: 27140836
    6. High NY-ESO-1 expression is associated with Lung Cancer. PMID: 27793776
    7. Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas. PMID: 27993576
    8. Data suggest that only a small fraction of HLA-A*02:01- (HA)-binding ESO peptides are immunogenic, namely those that have high peptide-binding strength and peptide/HA complex stability. This study involved comparison of in silico-predicted and observed cytotoxic T-lymphocyte recognition of tumor antigen epitopes in melanoma patients and transgenic/knockout mice. (ESO = tumor antigen NY-ESO-1) PMID: 28536262
    9. These data demonstrate that MAGE-A1-, MAGE-A3-, and NY-ESO-1-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible. PMID: 28677424
    10. Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan-MAGE or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS). PMID: 27466502
    11. MAGE-A is more highly expressed than NY-ESO-1 in a majority of human malignancies PMID: 27070449
    12. These cells were used to target a human lung cancer line that expressed NY-ESO-1. PMID: 26324743
    13. regulation of NY-ESO-1 processing by the ubiquitin receptors Rpn10 and Rpn13 as a well as by the standard and immunoproteasome is governed by non-canonical ubiquitination on non-lysine sites. PMID: 26903513
    14. CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors. PMID: 26191258
    15. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). PMID: 25412843
    16. High expression of NY-ESO-1 is associated with Triple-Negative Breast Cancer. PMID: 26413775
    17. NY-ESO-1 expression in melanoma was associated with tumor progression, including increased tumor thickness, and with reduced tumor infiltrating lymphocytes. PMID: 25954764
    18. NY-ESO-1 is expressed in esophageal adenocarcinomas, Barrett's metaplasia and normal tissues other than germ cells PMID: 24744590
    19. NY-ESO-1 cancer antigen expression has a role in immunotherapy in thyroid cancer PMID: 24811699
    20. primary autoantibodies against intracellular MM-specific tumor antigens SSX-2 and NY-ESO-1 are rare but functional in multiple myeloma patients after allogeneic stem cell transplantation PMID: 25078248
    21. We have also shown that NY-ESO-1 expression may lead to humoral immune response in patients with meningioma. PMID: 24777967
    22. NY-ESO-1 tetramer(+) cells were detected concomitantly with high proportions of Treg but were distinct from the latter and displayed characteristics of TH1 effectors. PMID: 24777968
    23. neck squamous cell carcinoma patients showing protein expression of MAGE-A family members or NY-ESO-1 represent a subgroup with an extraordinarily poor survival. PMID: 24482145
    24. Our observations indicate a tight link of NY-ESO-1 expression to ERG activation PMID: 24789172
    25. NY-ESO-1 and SP17 was not significantly associated with a specific histotype, but high-level GAGE expression was more frequent in squamous cell carcinoma. GAGE expression was demonstrated to be significantly higher in stage II-IIIa than stage I NSCLC. PMID: 24103781
    26. NY-ESO-1 appears to be a sensitive and a specific marker for myxoid and round cell liposarcoma among mesenchymal myxoid neoplasms. PMID: 23599152
    27. Positive results of immunohistostaining were obtained in 16 (35.6%), 7 (15.6%) and 36 (80.0%) samples using MAGE-C1, NY-ESO-1 and Sp17 antibodies, respectively PMID: 23923079
    28. study analyzed NY-ESO-1 expression in 222 melanoma specimens including 16 primary and 206 metastatic tumors; results support previous findings showing higher expression of NY-ESO-1 in metastatic (58/206) versus primary (0/16) tumors; results also show epithelioid subtype of melanoma has the highest incidence of NY-ESO-1 expression PMID: 24290058
    29. In two non epithelial cancers (glioma and mesothelioma), the epigenetic regulation of the NY-ESO-1 gene requires the sequential recruitment of the HDAC1-mSin3a-NCOR, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a complexes. PMID: 23312906
    30. Melanoma patients' humoral immune systems responded to NY-ESO-1 differently in each individual. PMID: 23454162
    31. CTAG1B mRNA and protein are overexpressed with high frequency in myxoid and round cell liposarcoma PMID: 22936067
    32. High CTAG1 expression and down-regulation of HLA class-I is associated with non-small cell lung cancer. PMID: 23645764
    33. NY-ESO-1 is strongly and diffusely expressed in a majority of synovial sarcomas, but only rarely in other mesenchymal lesions. Suggest roles in targeted therapy and differential diagnosis. PMID: 22388761
    34. The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma. PMID: 22529253
    35. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. PMID: 22323448
    36. Polymeric structure and TLR4 may play important roles in rendering NY-ESO-1 immunogenic and thus serve as a potent molecular adjuvant. NY-ESO-1 thus represents the first example of a cancer/testis antigen PMID: 21900253
    37. Integrated NY-ESO-1 immune responses may have predictive value for ipilimumab treatment in patients with advanced metastatic melanoma. PMID: 21933959
    38. Primary tumors with and without lymph node metastases showed no significant differences in MAGE-A 3/4 (P=0.672) and NY-ESO-1 (P=0.444) expression PMID: 21556122
    39. LAGE-1a and NY-ESO-1 homology cannot be easily exploited in an anti-NY-ESO-1 vaccine given the low frequency of protein expression detected by IHC or serum analysis. PMID: 21247062
    40. Report immunohistochemical expression of NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma. PMID: 20591578
    41. Most melanoma patients with spontaneous NY-ESO-1-specific responses in this study exhibit spontaneous CD4-positive T cell responses to at least one of the three immunodominant LAGE-1 epitopes. PMID: 21131422
    42. A versatile prime-boost vaccine strategy allows the generation of powerful, high-avidity tumor-associated immunodominant NY-ESO-1-transgene specific CD8-positive cytotoxic T cell responses. PMID: 20733200
    43. tumor antigen NY-ESO-1 has a role in the immune responses to tumor and self-antigens PMID: 20368442
    44. ESO 9V peptide isoform is more efficient in inducing conjugate formation and cytolytic granule polarization than the ESO 9L isoform. PMID: 20053942
    45. MAGE-A3/6 and NY-ESO-1 were expressed in 50.0% (66/132) and 18.2% (24/132) of non-small-cell lung carcinomas, respectively. PMID: 19795170
    46. High NY-ESO-1 expression is associated with oral squamous cell carcinoma. PMID: 20044626
    47. Postvaccine T-cell clones are shown to recognize and lyse NY-ESO-1 expressing tumor cell lines in vitro. PMID: 19728336
    48. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. PMID: 11782380
    49. NY-ESO-1 is a marker that can be used to follow the early progression of testicular tumorigenesiswhen the tumors express a similar pattern to the cells of origin,although later tumors cease to express NY-ESO-1. PMID: 12065688
    50. abilities of human monocyte-derived DCs and DCs derived in vitro from CD34-positive stem cells to present NY-ESO-1 epitopes to MHC class I-restricted cytotoxic T cells PMID: 12138174

    顯示更多

    收起更多

  • 亞細胞定位:
    Cytoplasm.
  • 蛋白家族:
    CTAG/PCC1 family
  • 組織特異性:
    Expressed in testis and ovary and in a wide variety of cancers. Detected in uterine myometrium. Expressed from 18 weeks until birth in human fetal testis. In the adult testis, is strongly expressed in spermatogonia and in primary spermatocytes, but not in
  • 數據庫鏈接:

    HGNC: 24198

    OMIM: 300156

    KEGG: hsa:1485

    STRING: 9606.ENSP00000332602

    UniGene: Hs.534310



主站蜘蛛池模板: 国产精品亲子乱子伦xxxx裸| 7777奇米四色成人眼影| 97精品国产一区二区三区| 琪琪女色窝窝777777| 色avav色av爱avav亚洲色拍| 亚洲自偷自偷偷色无码中文| 人妻丰满熟妇岳av无码区hd| 五十老熟妇乱子伦免费观看| 亚洲国产精品无码久久久动漫 | 免费看成人毛片无码视频| 亚洲精品成人区在线观看| 韩国精品一区二区三区四区| 韩国精品一区二区三区四区 | 日本高清www无色夜在线视频| 少妇性荡欲午夜性开放视频剧场| 亚洲一区二区三区高清av| 日日拍夜夜嗷嗷叫|日日摸| a欧美爰片久久毛片a片| 国产偷v国产偷v亚洲高清| 成人内射国产免费观看| 亚洲人成电影网站色迅雷| 人妻无码熟妇乱又伦精品视频| 国产偷窥熟女精品视频| 欧美另类videosbestsex日本| 国产99视频精品免费专区| 西西艺术人像摄影| 国产精品久久久久久久久久免费| 国产l精品国产亚洲区久久| 无码h肉动漫在线观看免费| 综合色就爱涩涩涩综合婷婷| 婷婷成人综合激情在线视频播放| 免费人成视频在线观看视频| 高潮内射双龙视频| 国产精品va无码免费| 日本真人做爰免费的视频| av国産精品毛片一区二区网站| 国产成人愉拍精品| 国产一区二区不卡老阿姨| 国内熟女啪啪自拍| 8x国产精品视频| 久久久久久自慰出白浆|